IL-1β and IL-18 release from APLAID patients’ PBMCs after LPS treatment was comparable to that of CAPS patients (Fig. 4c). This evidence concerns the gene IL1B and autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.